BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 9605156)

  • 1. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.
    Bour H; Horvath C; Lurquin C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Jun; 160(11):5522-9. PubMed ID: 9605156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
    Olver S; Groves P; Buttigieg K; Morris ES; Janas ML; Kelso A; Kienzle N
    Cancer Res; 2006 Jan; 66(1):571-80. PubMed ID: 16397274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
    Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
    J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo.
    Bour H; Michielin O; Bousso P; Cerottini JC; MacDonald HR
    J Immunol; 1999 Apr; 162(8):4647-56. PubMed ID: 10202004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping of HLA epitopes recognized by H-2-restricted cytotoxic T lymphocytes specific for HLA using recombinant genes and synthetic peptides.
    Pala P; Corradin G; Strachan T; Sodoyer R; Jordan BR; Cerottini JC; Maryanski JL
    J Immunol; 1988 Feb; 140(3):871-7. PubMed ID: 2448379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the HLA-Cw3-specific cytotoxic T lymphocyte response of HLA-B7 X human beta 2m double transgenic mice.
    Barra C; Pérarnau B; Gerlinger P; Lemeur M; Gillet A; Gibier P; Lemonnier FA
    J Immunol; 1989 Nov; 143(10):3117-24. PubMed ID: 2478616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirement for CD4 T cell help in generating functional CD8 T cell memory.
    Shedlock DJ; Shen H
    Science; 2003 Apr; 300(5617):337-9. PubMed ID: 12690201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN; Sharpe AH; Bluestone JA; Mokyr MB
    J Immunol; 1999 Apr; 162(8):4817-23. PubMed ID: 10202025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A; Shiku H; Nakayama E
    J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8+ T cell response.
    Kedl RM; Mescher MF
    J Immunol; 1998 Jul; 161(2):674-83. PubMed ID: 9670942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
    Apasov SG; Sitkovsky MV
    J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
    Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
    Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
    Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
    J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the minimum requirements for in vitro "cure" of tumor cells by cytotoxic T lymphocytes.
    Miki S; Ksander B; Streilein JW
    Reg Immunol; 1992; 4(6):352-62. PubMed ID: 1297406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.